Improving Profitability A Key Mid-Term Focus For Takeda
Executive Summary
CEO Christophe Weber remains resolutely upbeat on the progress of Takeda's strategic transformation plan, the dividends of which he said are apparent in the leading Japanese pharma firm's fiscal year performance.
You may also be interested in...
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.